Cumberland Emerging Technologies Appoints a New Senior Executive

Cumberland Emerging Technologies, or CET, is a joint initiative between Cumberland Pharmaceuticals, Vanderbilt University, LaunchTN, and Winhealth Pharma Group. Its mission is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace.

Orphan Drug Grant Funding for New Clinical Program!

We’ve initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. FDA has cleared our application to study ifetroban in DMD patients, 7 years of age and older.

Vibativ®, Acetadote®, Caldolor® and Methotrexate Update

Vibativ®, Acetadote®, Caldolor® and Methotrexate Update


Earlier this year, we announced a strategic review following our accelerated business development activities, that led toa series of transactions. Because of that progress, we took a fresh look at our portfolio, partners and organization to ensure we havethe proper focus and capabilities going forward. Below is a summary of our findings and decisions: